Hong Kong – September 16, 2026 -- Akeso, Inc. (9926.HK) reported that its bispecific antibody ivonescimab reduced the risk of death by 27% compared with Merck's pembrolizumab in a Phase III trial of PD-L1-positive non-small cell lung cancer (NSCLC), with results presented as a Late-Breaking Abstract at the 2026 World Conference on Lung Cancer (WCLC).

Seoul – September 12, 2026 -- SystImmune, Inc. announced that new global Phase 1 data support 2.5 mg/kg D1D8 Q3W as the recommended Phase 3 dose for iza-bren (izalontamab brengitecan), a bispecific EGFRxHER3 antibody drug conjugate, in previously treated EGFR-mutated metastatic non-small cell lung cancer (NSCLC).

Quebec – September 16, 2026 -- Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF) expects its common shares and warrants to begin trading on NYSE American LLC as early as September 16, 2026, under the ticker symbols "DHGR" and "DHGR WS."

Plymouth, Mich. – – September 16, 2026 -- Esperovax, Inc. has secured a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application No. 18/038,673, covering its engineered yeast platform for producing therapeutic proteins directly inside the body.

Indianapolis – September 16, 2026 -- Eli Lilly and Company (NYSE: LLY) has completed its acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions.

Milford, Mass. – September 16, 2026 -- Waters Corporation (NYSE: WAT) will have President and CEO Udit Batra, Ph.D., participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference on Wednesday, September 23, 2026.

Batra to address investors at 7:00 AM Eastern Time session

The fireside chat is scheduled for 12:00 PM BST (GMT+1), equivalent to 7:00 AM Eastern Time, on September 23, 2026.

Arlington, Mass. – – September 16, 2026 -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) has dosed the first two patients in the EXACT Study, a Phase 2b trial evaluating its investigational drug exaluren in patients with nonsense mutation Alport syndrome (NMAS), a rare kidney disease with no FDA-approved therapy targeting its genetic cause.

Valby, Denmark – – September 16, 2026 -- The U.S. Food and Drug Administration has granted Orphan Drug Designation to asedebart (Lu AG13909), Lundbeck's investigational anti-ACTH monoclonal antibody, for the treatment of endogenous Cushing's syndrome.

Seoul -- September 9, 2026 -- MegazoneCloud has begun system development on 'Hanmi Q-Agent,' an AI agent designed to cut Hanmi Pharmaceutical's quality assurance document workload by more than 40%, with build work starting September 7.

Tokyo – September 16, 2026 -- The Galien Foundation will hold the inaugural Prix Galien Japan Forum and Awards Ceremony on Thursday, February 25, 2027, at the Hotel New Otani in Tokyo, marking the first time the life sciences prize has been presented in Japan.